Relief Therapeutics Holding AG (RLFTF)

[djhfsu]

I found these two items in the paragraph to be very powerful in the new revised document:

"While VIP clearly prevents cytokine storm as shown below, its primary effect is to block viral replication in the first place
and to upregulate the production of surfactant that is critical to blood oxygenation. Hence, VIP represents the first COVID-19 therapeutic to
directly combat the replication of the SARS-CoV-2 virus at the site of injury."

Best.

Dave